SOLASTA Bio, an agricultural biotechnology company, has successfully raised $14 million in a Series A funding round. The funds aim to expedite the development of the company’s innovative peptide-based bioinsecticides, which are environmentally friendly and inspired by nature. These bioinsecticides target harmful insects while safeguarding beneficial species like bees, addressing a crucial need in global crop protection.
Previously, SOLASTA Bio made headlines with its advancements in bioinsecticide technology, focusing on natural solutions rather than synthetic chemicals. Unlike synthetic insecticides, which often pose risks to non-target species and face increasing regulatory scrutiny, SOLASTA Bio’s approach offers a more sustainable alternative. The company’s recent successful field trials in Europe, the UK, and the US further solidify its promising technology platform.
The Series A funding round was led by Forbion through its BioEconomy fund, with significant contributions from FMC Ventures, Corteva Inc., and existing investors such as Cavallo Ventures, Rubio Impact Ventures, and Scottish Enterprise. This brings the company’s total funding to $19 million. As part of this investment, Joy Faucher from Forbion will join SOLASTA Bio’s board of directors.
Successful Field Trials
In 2023, SOLASTA Bio’s insect control agents demonstrated high efficacy during field trials on multiple crops. This success is pivotal as it proves the effectiveness of their biopeptides in real-world conditions, making them a viable alternative to conventional chemical insecticides. The technology aims to protect crops while preserving essential pollinators, thus contributing to sustainable agriculture.
Strategic Expansion Plans
With the new funding, SOLASTA Bio will enhance its technology platform, scale up biomanufacturing, and expand field trials across key regions. Additionally, the company plans to grow its operations in the US and explore strategic opportunities beyond crop use, such as stored grain protection. The ultimate goal is to enter the market by 2027, significantly faster than traditional synthetic pest control products.
The global insecticides market is currently dominated by synthetic chemicals, which account for 94% of solutions. SOLASTA Bio aims to disrupt this trend with their bioinsecticides, offering a safer and more effective alternative. With an annual market opportunity of $27 billion, the company is well-positioned to make a significant impact. Moreover, the increasing regulatory pressures and consumer demand for non-chemical residues highlight the necessity for such innovations.
Co-founded by Shireen Davies and Prof. Julian Dow, SOLASTA Bio boasts a leadership team with extensive expertise in technology and agribusiness. The company is committed to addressing the urgent need to protect pollinators while enhancing agricultural productivity. With strong backing and a clear vision, SOLASTA Bio is poised to lead the transition toward sustainable crop protection.
